Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

WPD Pharmaceuticals Inc. (C:WBIO)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for WBIO within the last 6 months
Loading...
See all filings within the past 6 months

Company News

May 24, 2024 10:35 ET
CSE Bulletin: Reinstatement - WPD Pharmaceuticals Inc. (WBIO)
Toronto, Ontario--(Newsfile Corp. - Le 24 mai/May 2024) - Effective immediately, WPD Pharmaceuticals Inc. will be reinstated for trading.
Read full article
May 24, 2024 10:25 ET
Canadian Investment Regulatory Organization Trade Resumption - WBIO
VANCOUVER, BC, May 24, 2024 /CNW/ - Trading resumes in:
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
3.72
3.34
Price to Book - most recent quarter
--
2.29
2.17
Price to Cash Flow per share - TTM
--
12.16
11.23
Price to Free Cash Flow per share - TTM
--
8.53
18.13
See all valuations

Short Report

Date Number of Shares Shorted Net Change
Dec 31, 1969 0 0
Dec 31, 1969 0 0
Dec 31, 1969 0 0
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in clinical development stage and three in pre-clinical development. It operates its business primarily through WPD Poland, a subsidiary of and the operating branch of the Company. Its portfolio includes WPD101, Berubicin, and WPD103. WPD101 is a family of biopharmaceuticals in preclinical stages of development for targeted treatment of brain tumors with a global license. Berubicin is an anthracycline proven to cross the blood-brain barrier and able to reach brain tumors.

See business summary

 

Twitter

Search (past week) for $WBIO.CA

  • No tweets found